Immunotherapy May Work Better in Men Than in Women

The Lancet Oncologyrecently published a meta-analysis showing that a new generation of immunotherapies, melanoma and non-small cell lung cancers are among the cancer types in which these immune checkpoint inhibitors improve overall survival in both female and male patients, but men were found to benefit more from these medicines in terms of treatment. According to the research team, immune checkpoint inhibitors were twice as effective in men with advanced solid (organ) tumors as in women.
Currently approved immune checkpoint inhibitors are medicines composed of monoclonal antibodies that inhibit CTLA-4, PD-1 and PD-L1 molecules. These immunotherapies rapidly entered use by improving patient survival in cancers that can be difficult to treat, such as malignant melanoma skin cancer, non-small cell lung cancer, bladder cancer and head and neck cancer, through a mechanism that removes the immune system’s blindness to cancer.
The finding that immunotherapies were more effective in men should not be interpreted as meaning they are unsuitable for women. Rather, we need to better understand how these mechanisms work and clarify how treatments can be optimized for both sexes.
Biomarkers that help predict the effectiveness of immunotherapies, such as MSI, TMLand PD-L1, have begun to be used. This study suggests that sex differences may now also need to be considered when predicting immunotherapy response.
Details of the Study Findings
This comprehensive meta-analysis examined 20 studies involving 11,351 patients with solid tumors treated with cancer immunotherapies. Medicines used included ipilimumab (Yervoy), tremelimumab (MedImmune), nivolumab (Opdivo) and pembrolizumab (Keytruda).
Two-thirds of the patients were men, and one-third were women. Melanoma and non-small cell lung cancer were the most common cancer types. Renal (kidney) cell carcinoma, bladder cancer and head and neck cancer were the other cancers represented.
Results Differed Between Men and Women
Although both men and women benefited more from immunotherapies than from placebo or control groups, the risk of death among men receiving immune checkpoint treatment was reduced twice as much as in women. This advantage in men was not limited to small cell lung cancer.
Why Did Immunotherapy Produce Different Outcomes in Men and Women?
Sex-related genetic interactions in the immune system, hormones, the environment and microbiome composition are thought to influence immune checkpoint treatment.
Have Women Been Insufficiently Evaluated in Clinical Trials?
Although the number of people participating in the trials strengthens the findings, the small number of female patients who participated created limitations.
Women have been underrepresented in biomedical research for more than 20 years, and this research again highlights the low number of female participants in cancer immunotherapy studies. In nearly half of the clinical trials included in the meta-analysis, women represented less than one-third of the participants. This makes it difficult to reach firm conclusions about how important a person’s sex is as a factor in treatment.
Related Topics:
- What Is a Clinical Trial? Why Is It Important for Cancer Treatment and Patients?
- The Changing Face of Clinical Trials—One Comprehensive Protocol for Multiple Questions
The number of female patients in immunotherapy studies should be increased so that more reliable conclusions can be reached about whether findings obtained in men also apply to women. Different immunotherapeutic approaches for men and women may also be investigated.
Female patients should not be deprived of immunotherapies on the basis of these research results. In fact, designing studies specifically for women to better understand immunotherapy’s effects on them may lead to more positive outcomes.
Sources
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
The Lancet Oncology, 16 May 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.